ETFMG Treatments, Testing and Advancements ETF (GERM)
ETFMG Treatments, Testing and Advancements ETF operates in the Asset Management industry of the Financial Services sector, headquartered in Lisle, IL, US. The stock last traded at $19.16, down 0.29% on the session, giving a market capitalisation of $9.6M. Its beta of 1.02 implies it has historically moved more than the broad market.
This fund aims to replicate the investment performance of U.S.-listed companies, including equity shares and depositary receipts, that are primarily engaged in two sectors: either researching, developing, and bringing to market treatments or vaccines for infectious diseases, or producing, researching, and supplying biological diagnostic tests for patients. At least 80% of the fund's total assets will be invested in the specific securities that constitute its underlying index. It is important to note that this fund is structured as non-diversified.
ETFMG Treatments, Testing and Advancements ETF is most often compared with the following Financial Services names: